Cemiplimab

Drug Profile

Cemiplimab

Alternative Names: REGN 2810; SAR 439684

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cervical cancer; Non-small cell lung cancer
  • Phase II Basal cell cancer; Squamous cell cancer
  • Phase I/II Multiple myeloma
  • Phase I B cell lymphoma; Cancer; Head and neck cancer; Lymphoma; Malignant melanoma

Most Recent Events

  • 03 Oct 2017 Phase-III clinical trials in Cervical cancer (Recurrent, Metastatic disease, Second-line therapy or greater) in Australia, USA (IV) (NCT03257267)
  • 08 Sep 2017 Cemiplimab receives Breakthrough Therapy status for Squamous cell cancer (In adults, Metastatic disease) in USA
  • 08 Sep 2017 Sanofi and Regeneron Pharmaceuticals announce intention to submit a BLA to US FDA for Squamous cell cancer in first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top